Experience with neoadjuvant chemotherapy in patients with breast cancer

Khawaja Farhan Zahid, Muhammad Kamran Siddique, Neelam Siddiqui, Narjis Muzaffar, Muhammad Asim, Muhammad Azfar

نتاج البحث: المساهمة في مجلةمقالمراجعة النظراء

ملخص

Objective: To determine the response rates to neoadjuvant chemotherapy in patients with breast cancer. Methods: Medical records of 161 women with breast cancer, registered at Shaukat Khanum Memorial Cancer Hospital between July 2006 and March 2008 were retrospectively reviewed. Patients were stratified into two groups based on the type of chemotherapy received; Group A (Anthracycline based regimens), Group B (Anthracycline and Taxane based regimens). Response rate was noted. Results: Clinical complete response rates by clinical examination were significantly higher in Group B as compared to Group A in both primary disease in breast and axillary nodes (39% vs. 20.3%, p = 0.01; 72.7% vs. 30.7%, p = 0.01, respectively). There was no difference in response rates by imaging between groups A and B in breast and axillary lymph nodes (12.5% vs. 17%, p = 0.4; 66.6% vs. 70.4%, p = 0.4, respectively). There was no difference in pCR rates between Group A and B (9.1% vs. 14.2%, p = 0.35). However, multivariate analysis showed significant increase in pCR rates by addition of taxanes (p = 0.028), in patients with poorly differentiated tumours (p = 0.028) and in those with axillary node negative disease by palpation (p = 0.016). There was no statistically significant difference in breast conservation rates between group A and B (25.4% vs. 36.7%, p = 0.1). Conclusion: Addition of taxanes to anthracycline based regimens improved the pathological complete response in our patients with breast cancer.

اللغة الأصليةEnglish
الصفحات (من إلى)284-287
عدد الصفحات4
دوريةJournal of the Pakistan Medical Association
مستوى الصوت60
رقم الإصدار4
حالة النشرPublished - أبريل 2010
منشور خارجيًانعم

ASJC Scopus subject areas

  • ???subjectarea.asjc.2700.2700???

بصمة

أدرس بدقة موضوعات البحث “Experience with neoadjuvant chemotherapy in patients with breast cancer'. فهما يشكلان معًا بصمة فريدة.

قم بذكر هذا